Department of Pediatrics, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey.
Department of Medical Biology, School of Medicine, University of Health Sciences, Istanbul, Turkey.
Eur J Nutr. 2023 Aug;62(5):2155-2164. doi: 10.1007/s00394-023-03139-3. Epub 2023 Mar 30.
Recent studies indicate that dysbiosis of gut microbiota and low-grade inflammation are important pathogenic determinants of type two diabetes mellitus (T2DM). The aim of this study is to investigate the effects of Lactobacillus GG on glycemic control, lipid profile, inflammatory parameters, and some gene expression levels in individuals with T2DM.
In a randomized, placebo-controlled trial, 34 women, aged 30-60 years with T2DM consumed daily probiotics or placebo for 8 weeks. The probiotic group consumed 10 × 10 Cfu/day Lactobacillus rhamnosus GG ATCC 53,103 (LGG), approved by the TR Ministry of Food, Agriculture, and Livestock. Anthropometric measurements, food diary, fasting blood, and fecal samples were taken at baseline and post-treatment.
Fasting blood glucose was significantly decreased in probiotic (p = 0.049) and placebo (p = 0.028), but there was no difference between the groups. In the probiotic group, no significant difference was observed in HbA1c, fructosamine, lipid profile, and inflammatory variables compared to baseline. In this group, with LGG supplementation, mucin 2 and 3A (MUC2 and MUC3A) gene expressions increased more than ninefolds (p = 0.046 and p = 0.008, respectively) at post-treatment. Meanwhile, there was no significant change in any of the gene expressions in the placebo group. There was no significant difference in energy, protein, dietary fiber, and cholesterol intakes between placebo and probiotic groups during the study. However, daily fat intake (p = 0.003), body weight (p = 0.014), and body fat (p = 0.015) in the probiotic group were significantly decreased.
In this study, the effects of a single probiotic strain were investigated for 8 weeks. At the end of the study, although there was no finding that clearly reflected on the glycemic parameters of T2DM, its beneficial effects on the expression of mucin genes, which are responsible for weight loss and protection of intestinal barrier functions, cannot be denied. Further studies are needed to reveal the importance of these findings.
ID: NCT05066152, October 4, 2021 retrospectively registered in ClinicalTrials.gov PRS web site.
最近的研究表明，肠道微生物群落失调和低度炎症是 2 型糖尿病（T2DM）的重要发病决定因素。本研究旨在探讨鼠李糖乳杆菌 GG 对 T2DM 患者血糖控制、血脂谱、炎症参数和某些基因表达水平的影响。
在一项随机、安慰剂对照试验中，34 名年龄在 30-60 岁的 T2DM 女性每天服用益生菌或安慰剂 8 周。益生菌组每天摄入 10×10 CFU/天的鼠李糖乳杆菌 GG ATCC 53,103（LGG），该菌株已获得 TR 食品、农业和畜牧业部的批准。在基线和治疗后采集人体测量学指标、饮食日记、空腹血和粪便样本。
益生菌（p=0.049）和安慰剂（p=0.028）组的空腹血糖均显著降低，但两组间无差异。与基线相比，益生菌组的 HbA1c、果糖胺、血脂谱和炎症变量无显著差异。在该组中，补充 LGG 后，粘蛋白 2 和 3A（MUC2 和 MUC3A）基因表达分别增加了 9 倍以上（p=0.046 和 p=0.008）。同时，安慰剂组的任何基因表达均无显著变化。在研究过程中，安慰剂组和益生菌组的能量、蛋白质、膳食纤维和胆固醇摄入量之间无显著差异。然而，益生菌组的每日脂肪摄入量（p=0.003）、体重（p=0.014）和体脂（p=0.015）显著降低。
在这项研究中，我们研究了单一益生菌菌株对 8 周的影响。在研究结束时，虽然没有发现明显反映 T2DM 血糖参数的结果，但不能否认其对粘蛋白基因表达的有益作用，这些基因负责减轻体重和保护肠道屏障功能。需要进一步的研究来揭示这些发现的重要性。
注册号：NCT05066152，2021 年 10 月 4 日在 ClinicalTrials.gov PRS 网站上进行了回顾性注册。
